-
2
-
-
79955073198
-
-
Médecins Sans Frontières Access Campaign., [Accessed 22 April 2015]
-
Médecins Sans Frontières Access Campaign. Untangling the Web of antiretroviral price reductions: 17th edition. 2014. http://www.msfaccess.org/content/untangling-web-antiretrovir al-price-reductions17th-edition-%E2%80%93-july-2014.[Accessed 22 April 2015]
-
(2014)
Untangling the Web of Antiretroviral Price Reductions: 17th Edition
-
-
-
5
-
-
84887052771
-
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection
-
Walmsley S, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369:1807- 1818.
-
(2013)
N Engl J Med
, vol.369
, pp. 1807-1818
-
-
Walmsley, S.1
Antela, A.2
Clumeck, N.3
Duiculescu, D.4
Eberhard, A.5
Gutierrez, F.6
-
6
-
-
84903303497
-
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
-
Clotet B, Feinberg J, Lunzen J, Khuong-Josses MA, Antinori A, Dumitru I, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383:2222-2231.
-
(2014)
Lancet
, vol.383
, pp. 2222-2231
-
-
Clotet, B.1
Feinberg, J.2
Lunzen, J.3
Khuong-Josses, M.A.4
Antinori, A.5
Dumitru, I.6
-
7
-
-
84874411899
-
Once-daily dolutegravir versus raltegravir in antiretroviral- naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study
-
Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral- naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, noninferiority SPRING-2 study. Lancet 2013; 381:735-743.
-
(2013)
Lancet
, vol.381
, pp. 735-743
-
-
Raffi, F.1
Rachlis, A.2
Stellbrink, H.J.3
Hardy, W.D.4
Torti, C.5
Orkin, C.6
-
9
-
-
84897975407
-
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
-
Oliveira M, Mesplede T, Ouashie PL, Moisi D, Wainberg MA. Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS 2014; 28:813-819.
-
(2014)
AIDS
, vol.28
, pp. 813-819
-
-
Oliveira, M.1
Mesplede, T.2
Ouashie, P.L.3
Moisi, D.4
Wainberg, M.A.5
-
10
-
-
80053293363
-
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study
-
Hamers R, Wallis C, Kityo C, Siwale M, Mandaliya K, Conradie F, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011; 11:750-759.
-
(2011)
Lancet Infect Dis
, vol.11
, pp. 750-759
-
-
Hamers, R.1
Wallis, C.2
Kityo, C.3
Siwale, M.4
Mandaliya, K.5
Conradie, F.6
-
14
-
-
84931025652
-
Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol
-
Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC. Dolutegravir has no effect on the pharmacokinetics of oral contraceptives with norgestimate and ethinyl estradiol. Ann Pharmacother 2015; 49:784-789.
-
(2015)
Ann Pharmacother
, vol.49
, pp. 784-789
-
-
Song, I.H.1
Borland, J.2
Chen, S.3
Wajima, T.4
Peppercorn, A.F.5
Piscitelli, S.C.6
-
15
-
-
84878991956
-
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): A randomised, openlabel, noninferiority study
-
SECOND LINE study group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, openlabel, noninferiority study. Lancet 2013; 381:2091-2099.
-
(2013)
Lancet
, vol.381
, pp. 2091-2099
-
-
-
16
-
-
84904253549
-
Assessment of second-line antiretroviral regimens for HIV therapy in Africa
-
Paton N, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234-247.
-
(2014)
N Engl J Med
, vol.371
, pp. 234-247
-
-
Paton, N.1
Kityo, C.2
Hoppe, A.3
Reid, A.4
Kambugu, A.5
Lugemwa, A.6
-
17
-
-
79955073198
-
-
Médecins Sans Frontières Access Campaign. [Accessed 22 April 2015]
-
Médecins Sans Frontières Access Campaign. Untangling the Web of antiretroviral price reductions: 16th edition. 2013. http://www.msfaccess.org/content/untangling-web-antiretroviralprice- reductions-16th-edition. [Accessed 22 April 2015]
-
(2013)
Untangling the Web of Antiretroviral Price Reductions: 16th Edition
-
-
-
19
-
-
84879874721
-
Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose- ranging study
-
Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose- ranging study. AIDS 2013; 27:1771-1778.
-
(2013)
AIDS
, vol.27
, pp. 1771-1778
-
-
Stellbrink, H.J.1
Reynes, J.2
Lazzarin, A.3
Voronin, E.4
Pulido, F.5
Felizarta, F.6
|